Acute Coronary Syndrome – Pipeline Review, 2019

The conditions associated with sudden, reduced blood flow to the heart are known as an acute coronary syndrome. The acute coronary syndrome is commonly used to describe conditions such as unstable angina, non-ST-segment elevation myocardial infarction or heart attack, and ST-segment elevation myocardial infarction or heart attack. The symptoms of acute coronary syndrome include pain radiating from chest to shoulders, arms, upper abdomen, back, neck or jaw, nausea or vomiting, and diaphoresis, etc. The causes may include the low supply of oxygen to the cells, the clot obstructing the flow of the blood to the heart muscles, etc.

The diagnosis of acute coronary syndrome can be done using electrocardiogram, blood tests, coronary angiogram, echocardiogram, myocardial perfusion imaging, computerized tomography (CT) angiogram, and stress test. The treatment includes the use of medications such as thrombolytic drugs, nitroglycerin, anti-platelet drugs, beta blockers, angiotensin-converting enzyme (ACE) inhibitors, statins, etc. Additionally, coronary bypass surgery, angioplasty, and stenting are among other surgical methods for the treatment of the acute coronary syndrome.

 Academic research institutes and research laboratories have focused on studying and developing new treatment options for acute coronary syndrome. For instance; P2Y12 inhibitor, which is being studied by Samsung Medical Center, is currently in clinical trials for the study of safety and efficacy of P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel) safety over 6-month duration of dual anti-platelet therapy after acute coronary syndromes.

At present more than 75% of the pipeline candidates for acute coronary syndrome are in the phase-3 and phase-4 stage. Majority of the studies have been sponsored by universities and academic research institutes.

Report Description

The report on ‘Acute Coronary Syndrome – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Acute Coronary Syndrome. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Acute Coronary Syndrome.

The report on ‘Acute Coronary Syndrome – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• A thorough assessment of the pipeline products by areas such as development stage; the route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases, and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for Acute Coronary Syndrome
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Acute Coronary Syndrome
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary